Benign Prostatic Hyperplasia

Pharmacor -- September 2007

  Introduction:

Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate and symptoms associated with the ease and frequency of urination. The disease is common in men older than 50 and can significantly affect quality of life. The limited number of branded competitors, the increasing prevalence of BPH, expanding diagnosis and drug-treatment rates, and the need for more-effective and safer therapies combine to make BPH an attractive market for drug developers.

  Questions Answered in This Report:

Branded products in the alpha blocker and 5-alpha-reductase inhibitor (5-ARI) classes have driven sales in the BPH market over the past five years. However, top-selling products in each class will face generic competition by 2009. To what extent will generic erosion of key products affect sales in the BPH market?

As population demographics shift toward an elderly population, BPH prevalence will increase 14% over the 2006-2016 forecast period. To what extent will increased prevalence offset the effects of generic erosion in the BPH market over the next decade?

Thought-leading urologists tell us that more patients are being treated at the primary care level thanks to heightened awareness of prostate health among patients and physicians. To what extent will this trend affect BPH diagnosis and drug-treatment rates? How will it affect drug sales over the study period? What other changes in medical practice are expected to impact drug sales?

Emerging BPH therapies, such as phosphodiesterase 5 inhibitors, gonadotropin modulators, and fixed-dose combinations of alpha blockers and 5-ARIs, offer the promise of improved efficacy, side-effect profile, and/or dosing frequency over available treatment options. Does available clinical data support the use of emerging therapies over available generics? If so, to what extent will they affect market growth? What role will emerging therapies play in the BPH treatment algorithm?

  Scope:

Markets: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 28 country-specific interviews with urologists, primary care physicians, and other thought-leading experts in the field.

Epidemiology: Prevalence of BPH broken down into mild, moderate, and severe populations.

Emerging therapies: Phase II: 8 drugs; Phase III: 3 drugs; coverage of 3 select preclinical and Phase I products.

Market forecast features: Using a proprietary analogue generic erosion model and anticipated launch dates based on primary and secondary research, we forecast drug sales for the treatment of BPH through 2016.